Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1b/2 Study to Evaluate the Safety and Tolerability of VERU-111 in Men With Advanced Metastatic Castration Resistant Prostate Cancer

NCT03752099 is registered in ClinicalTrials.gov with Veru Inc. as lead sponsor.

NCT NCT03752099
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03752099 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1b/2 Study to Evaluate the Safety and Tolerability of VERU-111 in Men With Advanced Metastatic Castration Resistant Prostate Cancer
Lead sponsor
Veru Inc.
Phase
Phase 1/2
Overall status
Terminated
Start date
January 18, 2019
Completion date
March 15, 2023
Enrollment
80 (actual)
Sites
13

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic castration resistant prostate cancer